Table 1.
Demographics.
| Experiment | N | Analysis | Donor ID | Gender (F/M) | Age (year)Median (min-max), Mean (±SEM) | Cell viability % Median (min-max), Mean (±SEM) | Diagnosis |
|---|---|---|---|---|---|---|---|
| FGF19/CDCA 24 h | 13 | qPCR (n = 13) ELISA (n = 13) BA analysis (n = 5)# |
13,38#,183#, 188,189,192, 194,195,198, 359,414#,425#, 432# |
8/5 | 47.0 (0–77) 49.1 (±7.4) |
77.0 (62–94) 76.6 (±2.4) |
Donor (n = 5), CRC (n = 3), CCC (n = 2), Cholangitis (n = 1), Hyperoxaluria (n = 1), Neuroendocrine tumor (n = 1) |
| FGF19/CDCA 6 h | 10 | qPCR (n = 10) ELISA (n = 10) BA analysis (n = 5)# RNA sequencing (n = 3)† |
16†,38#,207, 210#,224†,226†, 359,414#,425#, 432# |
3/7 | 46.0 (0–76) 39.4 (±10.6) |
80.0 (71–94) 81.9 (±2.5) |
Donor (n = 3), CRC (n = 1), CCC (n = 1), HCC (n = 2) Hyperoxaluria (n = 1), Alagille syndrome (n = 1), MSUD (n = 1) |
| Endogenous FGF19 | 10 | qPCR (n = 10) ELISA (n = 10) BA analysis (n = 5)# RNA sequencing (n = 3)† |
16†,38#,39†, 219,375#†,414#, 425#,432#,444, 445 |
3/7 | 32.0 (0–76) 38.3 (±9.4) |
80.0 (66–86) 76.9 (±2.0) |
Donor (n = 5), CRC (n = 2), CCC (n = 1), MSUD (n = 1), Unknown (n = 1) |
| Time course | 3 | qPCR (n = 3) ELISA (N = 3) |
414,425,432 | 1/2 | 73.0 (27–76) 58.7 (±15.9) |
80.0 (71–86) 79.0 (±4.4) |
Donor (n = 2), CCC (n = 1) |
| siRNA | 3 | qPCR (n = 3) ELISA (n = 3) |
456,458,461 | 2/1 | 57 (12–76) 48.8 (±19.9) |
77.0 (72–87) 78.7 (±4.4) |
Donor (n = 1), CRC (n = 2) |
#Donors used for BA analysis.
†Donors used for RNA sequencing analysis.
CRC, colorectal metastasis; HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; MSUD, maple syrup urine disease.
Characteristics and number of livers used to isolate cells for the respective experiments.